Cited by 246Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 119 of the 123 references it cites were found in a registry or an index.

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Majidpoor, Jamal, Mortezaee, Keywan·2021·Clinical Immunology

DOI 10.1016/j.clim.2021.108707

Open this paper in CoChat — free account

Abstract

Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally considered as low immune-reactive cancers that represent either limited infiltration of immune cells or extensive infiltration of immunosuppressive T cells. Interaction between programmed death ligand 1 (PD-L1) with programmed death-1 receptor (PD-1) is important for immune evasion. Tumors positive for PD-L1 generally show higher responses to the immune checkpoint inhibition (ICI); however, the high presence of PD-L1 in a tumor is a predictor of poor prognosis. Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but responses to the ICI is meaningful. It seems that in a tumor both the PD-L1 expression and TIL infiltration is required for improving responses to the anti-PD-1/PD-L1 immunotherapy. Combination of anti-PD-1/PD-L1 with immune modulatory drugs, such as C-X-C chemokine receptor type 4 (CXCR4), poly (ADP-ribose) polymerase (PARP) or transforming growth factor (TGF)-β inhibitors has shown meaningful clinical benefits.

Integrity signals

Registry

Crossref · 10.1016/j.clim.2021.108707

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus
Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Show all 123 references

Sorted by citations

Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Al-Marzooqi, S. K., Jerobin, J., Altemani, F. H., Algehainy, N. A., Alanazi, M. A., Abou‐Samra, A., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,545
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,486
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Pang, K., Shi, Z., Wei, L., Yang, D. F., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J., Chen, Y.-A., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 268
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Marei, H. E. S., Hasan, A., Pozzoli, G., & Cenciarelli, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02902-0 · Cited by 269
Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion
Tian, W., Lei, N., Zhou, J., Chen, M., Guo, R., Qin, B., Li, Y., & Chang, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04510-8 · Cited by 162
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Antonarakis, E. S., Park, S. H., Goh, J. C. H., Shin, S. J., Lee, J., Mehra, N., McDermott, R., Sala‐González, N., Fong, P. C. C., Greil, R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00233 · Cited by 153
The current knowledge concerning solid cancer and therapy
Najafi, M., Majidpoor, J., Toolee, H., & Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22900 · Cited by 137
Self-citation
The impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 102
Self-citation
Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 101
The interactions of paclitaxel with tumour microenvironment
Yu, D., Lou, Z., Ma, F.-Y., & Najafi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108555 · Cited by 93
IL-2 based cancer immunotherapies: an evolving paradigm
Rokade, S., Mehta-Damani, A., Oft, M., & Emmerich, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433989 · Cited by 88
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Mortezaee, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119627 · Cited by 73
Self-citation
Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 88
RETRACTED: Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
Majidpoor, J., & Mortezaee, K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112419 · Cited by 71
Self-citation
Retracted
Chemotherapy‐Enabled Colorectal Cancer Immunotherapy of Self‐Delivery Nano‐PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance
Zhao, L., Zheng, R., Rao, X., Huang, C., Zhou, H., Yu, X., Jiang, X., & Li, S. (2024) · Advanced Science · doi:10.1002/advs.202309204 · Cited by 70
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
Pawłowska, A., Rekowska, A. K., Kuryło, W., Pańczyszyn, A., Kotarski, J., & Wertel, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310859 · Cited by 71
The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment
Zhang, P., Qin, C., Liu, N., Zhou, X., Chu, X., Lv, F., Gu, Y., Yin, L., Liu, J., Zhou, J., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121518 · Cited by 65
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
Wen, R. M., Stark, J. C., Marti, G. E., Fan, Z., Lyu, A., Garcia-Marques, F. J., Zhang, X., Riley, N. M., Totten, S. M., Bermudez, A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180282 · Cited by 61
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Rouzbahani, E., Majidpoor, J., Najafi, S., & Mortezaee, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113906 · Cited by 62
Self-citation
Interleukin-2 therapy of cancer-clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107836 · Cited by 59
Self-citation
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
Mortezaee, K., & Majidpoor, J. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00667-8 · Cited by 63
Self-citation
Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products
Lafta, H. A., AbdulHussein, A. H., Al-Shalah, S. A. J., Alnassar, Y. S., Mohammed, N. M., Akram, S. M., Qasim, M. T., & Najafi, M. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230201145909 · Cited by 61
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zhou, Z., Wang, H., Li, J., Jiang, X., Li, Z., & Shen, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127911 · Cited by 54
Integrated Machine Learning and Single-Sample Gene Set Enrichment Analysis Identifies a TGF-Beta Signaling Pathway Derived Score in Headneck Squamous Cell Carcinoma
Wu, S., Lv, X., Li, Y., Gao, X., Ma, Z., Fu, X., & Li, Y. (2022) · Journal of Oncology · doi:10.1155/2022/3140263 · Cited by 52
Normalization in tumor ecosystem: Opportunities and challenges
Mortezaee, K. (2021) · Cell Biology International · doi:10.1002/cbin.11655 · Cited by 49
Self-citation
Checkpoint inhibitor/interleukin‐based combination therapy of cancer
Mortezaee, K., & Majidpoor, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4659 · Cited by 45
Self-citation
The role of TGF-β in the tumor microenvironment of pancreatic cancer
Luo, Q., Hu, Z., Zhao, H., Fan, Y., Tu, X., Wang, Y., & Liu, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.10.019 · Cited by 48
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114646 · Cited by 45
Self-citation
The role of matrix stiffness in breast cancer progression: a review
Xu, R., Yin, P., Wei, J., & Ding, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1284926 · Cited by 45
Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer
Falcinelli, M., Alhity, G., Baron, S., Mampay, M., Allen, M. C., Samuels, M. E., Jones, W., Cilibrasi, C., Flaherty, R. L., Giamas, G., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.02.011 · Cited by 43
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment
Sun, B. L. (2021) · The Prostate · doi:10.1002/pros.24213 · Cited by 43
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
Zhang, Y., Cui, Q., Xu, M., Liu, D., Yao, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901772 · Cited by 45
Key promoters of tumor hallmarks
Mortezaee, K., & Majidpoor, J. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02074-9 · Cited by 42
Self-citation
Resveratrol in Cancer Therapy: From Stimulation of Genomic Stability to Adjuvant Cancer Therapy: A Comprehensive Review
Amini, P., Moazamiyanfar, R., Dakkali, M. S., Khani, A., Jafarzadeh, E., Moloudi, K., Khodamoradi, E., Johari, R., Taeb, S., & Najafi, M. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221014152759 · Cited by 43
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030526 · Cited by 43
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 41
Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated
Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2022) · Medical Oncology · doi:10.1007/s12032-022-01801-0 · Cited by 40
Self-citation
Nobiletin in Cancer Therapy; Mechanisms and Therapy Perspectives
Moazamiyanfar, R., Rezaei, S., Aliashrafzadeh, H., Rastegar‐Pouyani, N., Jafarzadeh, E., Moloudi, K., Khodamoradi, E., Zhaleh, M., Taeb, S., & Najafi, M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230426115424 · Cited by 39
Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
Li, J., Xuan, S., Dong, P., Xiang, Z., Gao, C., Li, M., Huang, L. J., & Wu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192506 · Cited by 39
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Self-citation
CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma
Zhang, R., Wang, J., Du, Y., Yu, Z., Wang, Y., Jiang, Y., Wu, Y., Le, T., Li, Z., Zhang, G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007529 · Cited by 36
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
(Im)maturity in Tumor Ecosystem
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.813897 · Cited by 34
Self-citation
Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy
Mehta, A., Motavaf, M., Nebo, I. D., Luyten, S., Osei-Opare, K. D., & Gru, A. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041200 · Cited by 38
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Macchini, M., Centonze, F., Peretti, U., Orsi, G., Militello, A. M., Valente, M. M., Cascinu, S., & Reni, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102262 · Cited by 34
VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated
Mortezaee, K., Majidpoor, J., & Najafi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121083 · Cited by 35
Self-citation
A pan-cancer multi-omics analysis of lactylation genes associated with tumor microenvironment and cancer development
Wu, Z., Wu, H., Dai, Y., Wang, Z., Han, H., Shen, Y., Zhang, R., & Wang, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27465 · Cited by 36
Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review)
Zhang, Q., Ding, J., Wang, Y., He, L., & Xue, F. (2022) · Oncology Reports · doi:10.3892/or.2022.8313 · Cited by 36
Immunoregulation by resveratrol; implications for normal tissue protection and tumour suppression
Lalani, A. R., Fakhari, F., Radgoudarzi, S., Rastegar‐Pouyani, N., Moloudi, K., Khodamoradi, E., Taeb, S., & Najafi, M. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13760 · Cited by 33
CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 34
Self-citation
Tumor Microenvironment Responsive CD8+ T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer
Chen, Q., Yin, H., He, J., Xie, Y., Wang, W., Xu, H., Zhang, L., Shi, C., Yu, J., Wu, W., et al. (2023) · Advanced Science · doi:10.1002/advs.202302498 · Cited by 30
Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer via Enhanced EGFR-Targeted Therapy and Immunotherapy
Wang, X., Zhu, X., Li, B., wei, X., Chen, Y., Zhang, Y., Wang, Y., Zhang, W., Liu, S., Liu, Z., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02925 · Cited by 29
Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
He, R., Yuan, X., Chen, Z., & Zheng, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109444 · Cited by 29
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
Qiu, X., Shi, Z., Tong, F., Lu, C., Zhu, Y., Wang, Q.-L., Gu, Q., Qian, X., Meng, F., Liu, B., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178791 · Cited by 28
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer
Zhang, T., Zheng, S., Yang, L., Li, X., Wu, J., Sun, Y., & Liu, G. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103112 · Cited by 28
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
Graff, J., Burotto, M., Fong, P. C. C., Pook, D. W., Zurawski, B., Kopp, R. M., Salinas, J., Bylow, K. A., Kramer, G., Ratta, R., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.007 · Cited by 31
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance
Antognelli, C., Mandarano, M., Prosperi, E., Sidoni, A., & Talesa, V. N. (2021) · Cancers · doi:10.3390/cancers13122965 · Cited by 26
An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer
Cui, Y., Zhang, W., Lü, W., Feng, Y., Wu, X., Zhuo, Z., Zhang, D., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1228235 · Cited by 27
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer
Wang, T., Wu, L., Wang, S., Shi, X., Liu, H., & Deng, W. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60451-0 · Cited by 25
Regulation of pancreatic cancer therapy resistance by chemokines
Gautam, S. K., Basu, S., Aithal, A., Dwivedi, N. V., Gulati, M., & Jain, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.010 · Cited by 26
Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer
Li, C., Wang, X., Xing, L., Chen, T., Li, W., Li, X., Wang, Y., Yang, C., & Yang, Q. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156051 · Cited by 24
Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas
Li, J., Zhang, S., Chen, S., Yuan, Y., Zuo, M., Li, T., Wang, Z., & Liu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1021678 · Cited by 24
Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives
Maselli, F. M., Giuliani, F., Laface, C., Perrone, M., Melaccio, A., Santis, P. D., Santoro, A. N., Guarini, C., Iaia, M. L., & Fedele, P. (2023) · Current Oncology · doi:10.3390/curroncol30060432 · Cited by 24
Dysregulated metabolism: A friend-to-foe skewer of macrophages
Mortezaee, K., & Majidpoor, J. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2095374 · Cited by 24
Self-citation
PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study
Silvestris, N., Argentiero, A., Brunetti, O., Sonnessa, M., Colonna, F., Delcuratolo, S., Luchini, C., Scarpa, A., Lonardi, S., Nappo, F., et al. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2011859 · Cited by 23
Synergistic targeting strategies for prostate cancer
Li, X., Han, Z., & Ai, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01042-6 · Cited by 22
SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis
Du, Z., Niu, S., Wang, J., Wu, J., Li, S., & Yi, X. (2021) · Autoimmunity · doi:10.1080/08916934.2021.1913582 · Cited by 21
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
Bersanelli, M., Verzoni, E., Cortellini, A., Giusti, R., Calvetti, L., Ermacora, P., Napoli, M. D., Catino, A., Guadalupi, V., Guaitoli, G., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102044 · Cited by 20
Priming immunity via herbal components and their nanomedicines for the treatment of cancer
Li, X., Gong, C., Naeem, A., Liu, J., Yang, M., Zhang, J., & Shang, H. (2024) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000135 · Cited by 22
Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression
Zhou, Y., Bai, M., Chen, L., Han, H., Hou, S., Wang, X., Fan, P., Han, S., Chen, F., Li, J., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02583-z · Cited by 24
Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
Yang, Z., Deng, Y., Cheng, J., Wei, S., Luo, H., & Liu, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695006 · Cited by 20
Cuproptosis-based layer-by-layer silk fibroin nanoplatform-loaded PD-L1 siRNA combining photothermal and chemodynamic therapy against metastatic breast cancer
Li, Z., Cheng, L., Xu, X. M., Jia, R., Zhu, S., Zhang, Q., Cheng, G., Wu, B., Liu, Z., Tong, X., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101298 · Cited by 19
A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer
Zhu, W., Feng, D., Shi, X., Li, D., Wei, Q., & Yang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1042118 · Cited by 20
Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis
Tuo, Z., Feng, D., Jiang, Z., Bi, L., Yang, C., & Wang, Q. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.06.12 · Cited by 19
Prosaposin, tumor‐secreted protein, promotes pancreatic cancer progression by decreasing tumor‐infiltrating lymphocytes
Miyahara, Y., Takano, S., Sogawa, K., Tomizawa, S., Furukawa, K., Takayashiki, T., Kuboki, S., & Ohtsuka, M. (2022) · Cancer Science · doi:10.1111/cas.15444 · Cited by 18
Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review
Ma, S., Li, L., Cai, H., Guo, T., & Zhang, L. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i2.81 · Cited by 18
A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity
Liu, X., He, H., Qi, M., Jiang, Z., Lin, B., Wang, X., Wang, D., Ma, M., Jiang, W., & Zhou, R. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07578-0 · Cited by 18
Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression
Tong, Q., Xu, J., Wu, A., Zhang, C., Yang, A., Zhang, S., Lin, H., & Lü, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112513 · Cited by 18
Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data
Deng, H., Wang, L., Wang, N., Zhang, K., Zhao, Y., Qiu, P., Qi, X., Zhang, D., Xu, F., & Liu, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-10515-z · Cited by 19
TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer
Dong, X., Dai, H., Lin, Y., Sheng, X., Li, Y., Wang, Y., Zhang, X., Jiang, S., Yin, W., & Lu, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04257-6 · Cited by 19
Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma
Liang, Z., Sun, R., Tu, P., Liang, Y., Li, L., Liu, F., Bian, Y., Yin, G., Zhao, F., Jiang, M. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944286 · Cited by 16
Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma
Song, M., Wang, L., Jiang, S., Liang, J., Li, W., Rao, W., Du, Q., Liu, G., Meng, H., Tang, L., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111601 · Cited by 19
Cellular immune states in SARS-CoV-2-induced disease
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016304 · Cited by 17
Self-citation
A Liquid–Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients
You, Q., Chen, J., Wu, X., Xue, Y., Sun, J., Wei, Y., Zheng, Q., Xue, X., Chen, D., & Xu, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065515 · Cited by 16
A novel immune score model predicting the prognosis and immunotherapy response of breast cancer
Lv, W., He, X., Wang, Y., Zhao, C., Dong, M., Wu, Y., & Zhang, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-31153-2 · Cited by 16
Senescence-associated lncRNAs indicate distinct molecular subtypes associated with prognosis and androgen response in patients with prostate cancer
Feng, D., Li, D., Wang, J., Wu, R., & Zhang, C. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0025 · Cited by 16
The Circular RNA circFGFR4 Facilitates Resistance to Anti-PD-1 of Triple-Negative Breast Cancer by Targeting the miR-185-5p/CXCR4 Axis
Wang, F., Lu, Q., Yu, H., & Zhang, X. (2023) · Cancer Management and Research · doi:10.2147/cmar.s411901 · Cited by 16
Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer
Pleiko, K., Haugas, M., Parfejevs, V., Panteļejevs, T., Parisini, E., Teesalu, T., & Riekstiņa, U. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.08.015 · Cited by 16
Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancer
Deng, H., Yao, H., Zhou, S., He, C., Huang, Y., Li, Y., Chen, H., & Shu, J. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101948 · Cited by 16
The Crosstalk between Nerves and Cancer—A Poorly Understood Phenomenon and New Possibilities
Benzaquen, D., Lawrence, Y. R., Taussky, D., Zwahlen, D. R., Oehler, C., & Champion, A. (2024) · Cancers · doi:10.3390/cancers16101875 · Cited by 17
Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
Wang, S., Nie, F., Yin, Q., Tian, H., Gong, P., Ju, J., Liu, J., Yang, P., & Yang, C. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03865-5 · Cited by 16
Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives
Song, Q., Javid, A., Zhang, G., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701485 · Cited by 15
Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer
Guo, W., Huai, Q., Zhou, B., Guo, L., Sun, L., Xue, X., Tan, F., Xue, Q., Gao, S., & He, J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03298-y · Cited by 15
CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy
Mu, Y., & Guan, X. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230324152532 · Cited by 15
Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ
Švajger, U., Tešić, N., & Rožman, P. J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107978 · Cited by 15
Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer
Li, E., Xu, J., Chen, Q., Zhang, X., Xu, X., & Liang, T. (2023) · Immunotherapy · doi:10.2217/imt-2021-0075 · Cited by 16
Extracellular vesicle-based checkpoint regulation and immune state in cancer
Mortezaee, K., & Majidpoor, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01837-2 · Cited by 14
Self-citation
Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer
David, T., Mallavialle, A., Faget, J., Alcaraz, L. B., Lapierre, M., du Roure, P. D., Laurent‐Matha, V., Mansouri, H., Jarlier, M., Martineau, P., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16291 · Cited by 14

Authors: Majidpoor, J., & Mortezaee, K.
Affiliations: Gonabad University of Medical Sciences (IR)
Kurdistan University of Medical Sciences (IR)
Corresponding author: Mortezaee, Keywan
ORCID: Majidpoor, Jamal
Mortezaee, Keywan
Venue: Clinical Immunology
Publisher: Elsevier BV
Published: 2021-05
Volume: 226
Pages: 108707
ISSN: 1521-6616 (ISSN-L)
DOI: 10.1016/j.clim.2021.108707
OpenAlex: W3134731856
Cited by: 236
References: 123
Citations by year: 2026: 11 · 2025: 24 · 2024: 77 · 2023: 60 · 2022: 42 · 2021: 22
FWCI: 6.36
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Clinical Immunology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: PD-1/PD-L1 blockade, immune checkpoint inhibitors, cold tumors, immune evasion, triple-negative breast cancer, colorectal cancer, tumor-infiltrating lymphocytes, PD-L1 expression, CXCR4, PARP inhibitors, TGF-β inhibitors, combination immunotherapy
MeSH terms: Immune Checkpoint Inhibitors, Humans, Immunologic Factors, Immunotherapy, Neoplasms, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks